Ozmosi | Tisagenlecleucel Drug Profile

Product Description

a CD19 CAR T-cell therapy for the treatment of patients with relapsed/refractory large B cell lymphoma (r/r LBCL). (Sourced from: http://neoimmunetech.com/news/page01_view.html?number=55)

Mechanisms of Action: CAR-T, CD19

Novel Mechanism: No

Modality: Autologous CAR-T

Route of Administration: Intravenous

FDA Designation: *

Approval Status: Approved

Approved Indications: None

Company: Novartis
Company Location: Europe
Company Founding Year: 1996
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Tisagenlecleucel

Countries in Clinic: Australia, Austria, Belgium, Brazil, Canada, China, Czech Republic, Denmark, France, Germany, Hungary, Italy, Japan, Netherlands, Norway, Poland, Romania, Singapore, Slovakia, South Korea, Spain, Sweden, Switzerland, Taiwan, United Kingdom, United States, Unknown Location

Active Clinical Trial Count: 19

Recent & Upcoming Milestones

Highest Development Phases

Phase 2: Leukemia|Mantle-Cell Lymphoma

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success	Latest Trial Update Date	Data Updated
JapicCTI-194897	JapicCTI-194897	P3	Active	Diffuse Large B-Cell Lymphoma\|B-Cell Marginal Zone Lymphoma\|Inflammation\|Follicular Lymphoma\|T-Cell Lymphoma	2025-10-03
2015-003736-13	2015-003736-13	P2	Active, not recruiting	Lymphoma, B-Cell\|Leukemia	2027-09-04		2025-06-18	Primary Completion Date\|Start Date\|Study Completion Date\|Treatments\|Trial Status
NCT04234061	TARMAC	P2	Active, not recruiting	Mantle-Cell Lymphoma	2027-09-01		2021-10-22	Primary Endpoints\|Treatments\|Trial Status
NCT05888493	LEDA	P3	Active, not recruiting	Follicular Lymphoma	2028-07-25	11%	2026-02-18	Patient Enrollment\|Primary Endpoints\|Study Completion Date\|Treatments\|Trial Status
NCT04094311	CCTL019B2302	P3	Recruiting	Diffuse Large B-Cell Lymphoma\|Burkitt Lymphoma\|B-Cell Leukemia\|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma\|Acute Lymphoid Leukemia\|Precursor Cell Lymphoblastic Leukemia-Lymphoma	2027-03-31	59%	2026-02-18	Primary Completion Date\|Primary Endpoints\|Study Completion Date\|Treatments
2023-508343-48-00	CCTL019H2301	P3	Active, not recruiting	Lymphoma, B-Cell\|Lymphoma, Non-Hodgkin	2026-02-14	61%	2025-05-02	Treatments
2017-002849-30	2017-002849-30	P2	Active, not recruiting	B-Cell Leukemia\|Lymphoma, B-Cell	2023-02-23		2022-03-13	Treatments
2017-005019-15	BIANCA	P2	Active, not recruiting	Lymphoma, Non-Hodgkin\|Lymphoma, B-Cell	2022-10-08		2025-05-06	Treatments
2023-503452-27-00	CCTL019E2301	P3	Recruiting	Lymphoma, Non-Hodgkin\|Lymphoma, B-Cell\|Follicular Lymphoma	2031-02-20	11%	2025-05-02	Treatments
CTR20200561	CTR20200561	P3	Completed	Lymphoma, B-Cell\|Lymphoma, Non-Hodgkin	2026-02-03		2026-02-15	Patient Enrollment\|Primary Completion Date\|Study Completion Date\|Treatments\|Trial Status
JapicCTI-194988	JapicCTI-194988	P3	Active	Diffuse Large B-Cell Lymphoma\|Acute Lymphoid Leukemia\|B-Cell Leukemia\|Follicular Lymphoma	2022-06-30
JapicCTI-194622	JapicCTI-194622	P3	Planned	B-Cell Leukemia\|Acute Lymphoid Leukemia	None
NCT07676877	OSU-25255	P1	Not yet recruiting	Diffuse Large B-Cell Lymphoma	2027-12-31	12%	2026-07-01	Primary Endpoints
jRCT1080224903	jRCT1080224903	P3	Recruiting	Follicular Lymphoma\|Diffuse Large B-Cell Lymphoma	None
NCT04890236	DEEP T CELLS	P1	Completed	Diffuse Large B-Cell Lymphoma	2024-03-20		2025-01-22	Patient Enrollment\|Primary Completion Date\|Primary Endpoints\|Study Completion Date\|Treatments\|Trial Status
2023-508081-15-00	CCTL019G2201J	P2	Active, not recruiting	Acute Lymphoid Leukemia\|B-Cell Leukemia	2028-08-30		2025-05-02	Treatments
NCT03876769	CASSIOPEIA	P2	Active, not recruiting	Acute Lymphoid Leukemia\|Lymphoma, B-Cell\|Burkitt Lymphoma\|B-Cell Leukemia	2027-10-19	47%	2026-06-04
NCT05460533	REFUEL	P2	Active, not recruiting	B-Cell Leukemia\|Acute Lymphoid Leukemia\|Burkitt Lymphoma\|Lymphoma, B-Cell	2027-07-01	12%	2026-02-05	Patient Enrollment\|Primary Completion Date\|Primary Endpoints\|Study Completion Date\|Treatments\|Trial Status
2023-508127-13-00	CCTL019E2202	P2	Completed	Follicular Lymphoma	2025-03-27		2025-05-02	Treatments

Recent News Events

Date	Type	Title
04/21/2026	News Article	Verismo Therapeutics Presents Preclinical Data at AACR 2026 for SynKIR™-310 KIR-CAR Indicating Superior Preclinical Activity in B Cell Malignancies and Early Clinical Efficacy
04/02/2026	News Article	Feinstein Institutes 2026 Ross Prize awarded to Drs. Michel Sadelain and Carl H. June
03/03/2026	News Article	Hematologic Malignancies Market to Reach USD 128.48 Billion by 2032, Driven by Immunotherapy, CAR-T, and Precision Oncology - Credence Research Inc.
01/21/2026	News Article	KOMO Biosciences Appoints Patient Advocate Tom Whitehead and Immunotherapy Pioneer Michael Kalos, Ph.D. to Advisory Board

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

Tisagenlecleucel

Alternative Names: tisagenlecleucel, ctl-019, ctl019, ctl 019, Kymriah Clinical Status: Active Latest Update: 2026-07-02 Latest Update Note: Clinical Trial Update